MA55729A - Procédés de traitement de sujets atteints d'arthrite psoriasique - Google Patents

Procédés de traitement de sujets atteints d'arthrite psoriasique

Info

Publication number
MA55729A
MA55729A MA055729A MA55729A MA55729A MA 55729 A MA55729 A MA 55729A MA 055729 A MA055729 A MA 055729A MA 55729 A MA55729 A MA 55729A MA 55729 A MA55729 A MA 55729A
Authority
MA
Morocco
Prior art keywords
methods
psoriatic arthritis
treating subjects
subjects
treating
Prior art date
Application number
MA055729A
Other languages
English (en)
French (fr)
Inventor
Kirti Wardhaman Ganorkar
Anil Raghavan
Atul Mathuradas Raut
Siu-Long Yao
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MA55729A publication Critical patent/MA55729A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA055729A 2019-04-15 2020-04-15 Procédés de traitement de sujets atteints d'arthrite psoriasique MA55729A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN202021004422 2020-01-31

Publications (1)

Publication Number Publication Date
MA55729A true MA55729A (fr) 2022-02-23

Family

ID=72837755

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055729A MA55729A (fr) 2019-04-15 2020-04-15 Procédés de traitement de sujets atteints d'arthrite psoriasique

Country Status (16)

Country Link
US (1) US20220298233A1 (enExample)
EP (1) EP3956357A4 (enExample)
JP (2) JP7628962B2 (enExample)
KR (1) KR20210140780A (enExample)
CN (1) CN113825768A (enExample)
AU (1) AU2020259375A1 (enExample)
BR (1) BR112021020612A2 (enExample)
CA (1) CA3143604A1 (enExample)
IL (1) IL287213A (enExample)
JO (1) JOP20210279A1 (enExample)
MA (1) MA55729A (enExample)
MX (1) MX2021012652A (enExample)
MY (1) MY210310A (enExample)
PH (1) PH12021552536A1 (enExample)
SG (1) SG11202111056YA (enExample)
WO (1) WO2020212874A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202521154A (zh) * 2023-08-11 2025-06-01 大陸商信達生物製藥（蘇州）有限公司 既往接受生物製劑治療斑塊狀銀屑病的受試者轉用抗ＩＬ２３ｐ１９抗體治療斑塊狀銀屑病的方法
WO2025051249A1 (zh) * 2023-09-07 2025-03-13 信达生物制药(苏州)有限公司 一种重组抗IL-23p19抗体治疗中重度银屑病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
BRPI0807710B1 (pt) * 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
PT2635601T (pt) * 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
WO2014004436A2 (en) * 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies

Also Published As

Publication number Publication date
BR112021020612A2 (pt) 2021-12-28
MX2021012652A (es) 2022-01-24
CN113825768A (zh) 2021-12-21
KR20210140780A (ko) 2021-11-23
MY210310A (en) 2025-09-10
PH12021552536A1 (en) 2022-07-04
JP2025069284A (ja) 2025-04-30
US20220298233A1 (en) 2022-09-22
JP2022529266A (ja) 2022-06-20
CA3143604A1 (en) 2020-10-22
EP3956357A4 (en) 2023-01-04
EP3956357A1 (en) 2022-02-23
SG11202111056YA (en) 2021-11-29
WO2020212874A1 (en) 2020-10-22
JOP20210279A1 (ar) 2023-01-30
IL287213A (en) 2021-12-01
JP7628962B2 (ja) 2025-02-12
AU2020259375A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EP3781214A4 (en) Compositions and methods for treating spinal muscular atrophy
MA52640A (fr) Procédés de traitement de cancers et d'amélioration de l'efficacité d'agents thérapeutiques de redirection de lymphocytes t
MA51103A (fr) Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
EP3805726A4 (en) INSPECTION SYSTEM AND INSPECTION PROCEDURES
EP3297729A4 (en) ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT-CHAINED AMYLOIDOSES AND OTHER CD38-POSITIVE HEMATOLOGICAL MALIGNITIES
EP3982261A4 (en) METHOD AND APPARATUS FOR I/O PROCESSING
EP3950935A4 (en) Method for producing immunocytes, and use thereof
EP3390357A4 (en) BIARYL-MONOBACTAM COMPOUNDS AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS
MA53558A (fr) Compositions et procédés pour le traitement d'infections virales
MA71705A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
EP3930600A4 (en) DEVICES AND METHODS FOR TREATMENT OF EDEMA
MA55515A (fr) Procédés de traitement de la dystrophie musculaire avec casimersen
EP3908601A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3522900A4 (en) CONNECTIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF VIRUS INFECTIONS
MA55209A (fr) Procédés de traitement de l'amylose al
EP3801510A4 (en) METHODS OF TREATMENT OF MUSCULAR DYSTROPHIES
EP3775171A4 (en) METHODS OF TREATMENT OF MINIMAL RESIDUAL CANCER
EP3863615A4 (en) METHODS OF TREATMENT OF CANCERS WITH SOLID TUMORS USING ILLUDINS AND BIOMARKERS
EP3399995A4 (en) METHOD FOR PREVENTING AND TREATING PNEUMOCYSTIS INFECTIONS
EP3705182A4 (en) Method for producing self-fitting nano-catalyst sewage treatment agent
MA55087A (fr) Compositions et procédés de traitement de laminopathies
EP3781584A4 (en) 4'-THIO-NUCLEOTIDE AND NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER